Improving Pre-operative Systemic Therapy for Human Epidermal Growth Factor Receptor 2 (HER2) Amplified Breast Cancer
- Status
- TERMINATED
- Phase
- PHASE2
Clinical Trials Related to Pertuzumab
Related studies linked through entity extraction aliases.
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
- Status
- TERMINATED
- Phase
- PHASE1
Durvalumab With Trastuzumab and Pertuzumab in HER2-Enriched Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study to Compare Pertuzumab + Trastuzumab + Vinorelbine vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-positive Metastatic Breast Cancer
- Status
- WITHDRAWN
- Phase
- PHASE3
Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab [IIT2018-04-MCARTHUR-NEOHP]
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE3
DAPHNe: Paclitaxel/Trastuzumab/Pertuzumab in HER2-Positive BC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
To Reduce the Use of Chemotherapy in Postmenopausal Patients With ER-positive and HER2-positive Breast Cancer (TOUCH)
- Status
- COMPLETED
- Phase
- PHASE2
Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site
- Status
- COMPLETED
- Phase
- PHASE2
Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC
- Status
- COMPLETED
- Phase
- PHASE2
Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 Signaling
- Status
- UNKNOWN
- Phase
- PHASE2
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
- Status
- COMPLETED
- Phase
- PHASE2
Neoadjuvant Dose-Dense For Early Her2Neu Positive Breast Cancer
- Status
- TERMINATED
- Phase
- PHASE2
Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
A Study to Compare Eribulin Mesylate + Pertuzumab + Trastuzumab With Paclitaxel or Docetaxel + Pertuzumab + Trastuzumab
- Status
- COMPLETED
- Phase
- PHASE3
Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer
- Status
- TERMINATED
- Phase
- PHASE3
Biomarker Study of Immune-mediated Mechanism of Action of Neoadjuvant Trastuzumab in HER2+ Breast Cancer Patients
- Status
- UNKNOWN
- Phase
- PHASE2
Trastuzumab and Pertuzumab in Combination With Tocilizumab in Subjects With Metastatic HER2 Positive Breast Cancer Resistant to Trastuzumab
- Status
- COMPLETED
- Phase
- PHASE1
Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2